ublituximab MS
Selected indexed studies
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. (N Engl J Med, 2022) [PMID:36001711]
- Ublituximab: First Approval. (Drugs, 2023) [PMID:36920653]
- Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy. (Drug Des Devel Ther, 2024) [PMID:39050801]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. (2022) pubmed
- Ublituximab: First Approval. (2023) pubmed
- Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis. (2023) pubmed
- Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials. (2024) pubmed
- Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. (2023) pubmed
- Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. (2022) pubmed
- Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. (2024) pubmed
- Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. (2024) pubmed
- Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy. (2024) pubmed
- Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. (2023) pubmed